United Kingdom Information and Enquiries
On 27 June, 2025, BioCryst announced the sale of our European business to Neopharmed Gentili. You can read the press release here.
Medicines in the United Kingdom
The content on this page is intended for members of the public. Our current prescription medicines are listed below. If you click on the links below, you will be redirected to the Medicines and Healthcare products Regulatory Agency (MHRA), which contains easily accessible information about licensed medicines available in the United Kingdom. The MHRA website contains the Summary of Product Characteristics (SPC) and Patient Information Leaflets (PIL) for our medicines.
ORLADEYO® (berotralstat) SPC and PIL
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may develop. See yellowcard.mhra.gov.uk for how to report side effects.
Customer Assistance
Medical Information
For medical information:
medinfoeurope@biocryst.com or +44 (0)20 3885 0789
Healthcare professionals can access our UK HCP site at hcp.biocryst.co.uk
Adverse events/product complaints
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk
Adverse events should also be reported to BioCryst at:
medinfoeurope@biocryst.com or +44 (0)20 3885 0789
General enquiries
For general enquiries:
enquiries@biocryst.co.uk
BioCryst UK Limited (office)
No 5, The Heights, Brooklands Business Park, Weybridge, Surrey KT13 ONY
England
+44 (0) 1932 809 913
Disclosures
Healthcare professionals: We disclose the details of payments and other benefits to healthcare professionals (HCPs) and healthcare organisations (HCOs) on the ABPI database, Disclosure UK.
Contributions to patient organisations:
Contributions to members of the public, including patients: